At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 199 enrolled
Drug / intervention
AVANZ Phleum pratensedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Trial to Assess the Tolerability of AVANZ Phleum Pratense Immunotherapy
In Brief
A Phase 3 clinical trial evaluating AVANZ Phleum pratense for Allergic Rhinoconjunctivitis. Completed, enrolled 199 participants across 20 sites.
Detailed Summary
The purpose of this study is to assess the tolerability of AVANZ.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinoconjunctivitis
CountriesSpain
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedOct 2011
Primary CompletionMar 2012
Study CompletionApr 2012
TodayJul 2026
First PostedOct 19, 2011
Enrollment StartJun 1, 2011
Primary CompletionMar 1, 2012
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.7 years ago
Interventions
AVANZ Phleum pratensedrug
AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection